La cadena de opciones muestra datos clave de las opciones de acciones de Orthofix Medical a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Orthofix Medical..

Orthofix Medical (NASDAQ:OFIX) Bolsa, Cadena de Opciones

ORTHOFIX MEDICAL INC

Orthofix Medical

Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two main segments: global spine, including bone growth and healing therapies, spinal implants, and regenerative tissue products; and global orthopedics, providing products used in fracture repair, deformity correction, and bone reconstruction procedures. The majority of the company's sales come from the global spine segment in the United States. Orthofix distributes its products throughout North America, Europe, and several countries across the globe. The company provides solutions to hospitals, physicians, other healthcare providers, and patients.

News

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

GMED

OFIX

Orthofix Medical (OFIX) y Globus Medical (GMED) muestran niveles de RSI por encima de 70. ¿Es momento de vender?

¿Señal de alerta? Estas acciones de salud están sobrecompradas

ALTG

Alterity Therapeutics Limited - American Depositary Shares

ATHE

CARM

CNCK

CRGX

FBNC

MGOL

NAOV

NATR

RNGR

SLXN

TSLA

VREX

XFOR

Meta sube en la preapertura tras superar expectativas. Descubre qué otras acciones están registrando fuertes movimientos hoy.

Acciones de Meta Platforms (META) están cotizando al alza; 20 acciones que se mueven en el premercado de EE.UU.

Movers

ALVO

BBGI

BCAX

ELTX

FOXO

ISPC

JBHT

LYTS

MDXG

NUKK

TMCI

TXNM

VIAV

WILC

Explora los mayores ganadores y perdedores en las operaciones previas al mercado. Descubre qué impulsó estos movimientos destacados.

Las acciones de Versus Systems (VS) aumentan un 71%; 20 acciones que se mueven en el premercado de EE.UU.

Barrington Research analyst Michael Petusky initiates coverage on Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) with a Outperform rating and announces Price Target of $16.

Price Target

Initiation

Analyst Ratings

Barrington Research Initiates Coverage On Orthofix Medical with Outperform Rating, Announces Price Target of $16

Orthofix Announces Global Launch Of TrueLok Elevate To Address Diabetic Ulcers And Limb Preservation Needs

JMP Securities analyst David Turkaly reiterates Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) from Market Perform to Market Perform.

Reiteration

JMP Securities Reiterates Market Perform on Orthofix Medicalto Market Perform

WIIM

Orthofix Medical shares are trading lower after the company cut its FY25 sales guidance below estimates.

Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) lowers FY2025 sales outlook from $818.00 million-$826.00 million to $808.00 million-$816.00 million vs $821.98 million estimate.

Guidance

Orthofix Medical Lowers FY2025 Sales Guidance from $818.00M-$826.00M to $808.00M-$816.00M vs $821.98M Est

Earnings

Earnings Beats

Orthofix Medical Q1 Adj. EPS $(0.08) Beats $(0.27) Estimate

Orthofix Medical Q1 Sales $193.65M Beat $191.10M Estimate

ACLS

AHCO

ALAB

ALGS

ALGT

AMTM

ANDE

ANET

ANGI

ARDT

ARIS

ARMK

ARQT

ARRY

ATKR

ATOM

ATRO

AUDC

AVNS

AVNT

AVNW

AZEK

BALL

BBNX

BCAB

BLDP

BRLT

BWIN

BWMN

CCCS

CCLD

CDRE

CELH

CGAU

CGBD

CHMI

CHRD

CIFR

CIGI

CLDT

CLOV

COTY

CPAY

CPIX

CPNG

CRCT

CRIS

CRMD

CRSR

CRUS

CURI

CVGI

CXDO

CYTK

DASH

DAWN

DDOG

DOCN

DRCT

DRVN

DVAX

ENLT

EOSE

Embraer-Empresa Brasileira De Aeronautica

ESPR

EVGO

Earnings Scheduled For May 6, 2025

Orthofix Receives FDA 510(k) Clearance And European CE Mark For The TrueLok Elevate Transverse Bone Transport System

Canaccord Genuity analyst Caitlin Burrows maintains Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) with a Buy and maintains $24 price target.

Canaccord Genuity Maintains Buy on Orthofix Medical, Maintains $24 Price Target

Roth MKM analyst Jason Wittes reiterates Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) with a Buy and maintains $22 price target.

Roth MKM Reiterates Buy on Orthofix Medical, Maintains $22 Price Target

Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) sees FY2025 sales of $818.000 million-$826.000 million vs $847.01 million analyst estimate.

Orthofix Medical Sees FY2025 Sales $818.000M-$826.000M vs $847.01M Est

Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.05) by 140 percent. This is a 103.39 percent increase over losses of $(0.59) per share from the same period last year. The company reported quarterly sales of $215.66 million which beat the analyst consensus estimate of $212.71 million by 1.38 percent. This is a 7.61 percent increase over sales of $200.41 million the same period last year.

Orthofix Medical Q4 Adj $0.02 Beats $(0.05) Estimate, Sales $215.66M Beat $212.71M Estimate

ALLT

AXGN

AXON

BASE

BGFV

BLZE

BTDR

CART

CAVA

CBLL

CECO

CPSS

DNUT

ELAN

EXLS

FIHL

FLYW

FSLR

FULC

GPOR

HRMY

HSIC

HURN

HYLN

IART

ICCC

IGIC

IMOS

INGN

INTU

INVX

IPAR

ITRI

IVAC

JACK

JAZZ

KEYS

KNSA

LCID

LGIH

LIVN

LMND

LXFR

MASI

MATX

MFIC

MIDD

MMSI

MPLN

MRVI

NOVT

NXRT

Earnings Scheduled For February 25, 2025

As of Feb. 5, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the<a href="https://www.benzinga.com/topic/rsi"> RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Orthofix Medical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>)</h3>
<ul>
<li>Orthofix Medical announced that it will release its fourth quarter and full-year 2024 financial results on Tuesday, Feb. 25, 2025 before the opening bell. The company has a <a href="https://www.benzinga.com/quote/OFIX">52-week high of $20.73</a>.</li>
<li>RSI Value: 77.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>OFIX Price Action: Shares of Orthofix Medical gained 3.1% to close at $18.76 on Tuesday.</li>
</ul>
<h3 class="wp-block-heading">Globus Medical Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>)</h3>
<ul>
<li>On Feb. 3, Interactive Brokers reported a year-over-year increase in daily average revenue trades for January. The company's stock gained around 10% over the past month and <a href="https://www.benzinga.com/quote/GMED">has a 52-week high</a> of $94.93.</li>
<li>RSI Value: 74</li>
<li>GMED Price Action: Shares of Globus Medical fell 0.4% to close at $92.18 on Tuesday.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43460681/jim-cramer-says-no-to-bigbear-ai-recommends-buying-this-tech-stock">Jim Cramer Says No To BigBear.ai, Recommends Buying This Tech Stock</a></li>
</ul>

Top 2 Health Care Stocks That May Crash In February

Shares of Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) rose sharply in today's pre-market trading after the company reported better-than-expected <a href="https://www.benzinga.com/general/social-media/25/01/43322201/meta-platforms-q4-earnings-revenue-beat-eps-beat-daily-actives-up-5-continued-strong-revenue-growth-expected">fourth-quarter sales results</a>.
Meta reported fourth-quarter revenue of $48.39 billion, beating analyst estimates of $47.03 billion. The company reported fourth-quarter earnings of $8.02 per share, beating analyst estimates of $6.77 per share.
Meta shares gained 2.2% to $691.66 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Alterity Therapeutics Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) gained 105% to $6.13 in pre-market trading.</li>
<li>NanoVibronix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) rose 54.1% to $0.5853 in pre-market trading.</li>
<li>X4 Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XFOR#NASDAQ">XFOR</a>) gained 40.1% to $1.03 in pre-market trading after jumping more than 52% on Wednesday.</li>
<li>MGO Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGOL#NASDAQ">MGOL</a>) gained 21.9% to $0.1240 in pre-market trading after dipping over 38% on Wednesday.</li>
<li>Carisma Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARM#NASDAQ">CARM</a>) gained 18.4% to $0.5980 in pre-market trading.</li>
<li>Alta Equipment Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALTG#NYSE">ALTG</a>) rose 14.1% to $8.01 in pre-market trading.</li>
<li>Celestica Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) shares jumped 13.1% to $113.66 in pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued FY25 guidance above estimates.</li>
<li>Ranger Energy Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNGR#NYSE">RNGR</a>) gained 10.5% to $19.00 in pre-market trading.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rose 2.9% to $400.23 in pre-market trading. Tesla reported weaker-than-expected fourth-quarter earnings and sales results. The company, meanwhile, said it expects its vehicle business to return to growth in 2025. Tesla also promised to launch new and &#8220;more affordable&#8221; models in the first half of 2025, in addition to other promises regarding the deployment of autonomous vehicles and licensing of the company&#8217;s full self-driving (FSD) driver assistance software to rivals.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>CARGO Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGX#NASDAQ">CRGX</a>) shares fell 74.3% to $3.39 in pre-market trading after the company announced it discontinued its FIRCE-1 Phase 2 study.</li>
<li>Nature&#8217;s Sunshine Products, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NATR#NASDAQ">NATR</a>) dipped 46.6% to $8.00 in pre-market trading.</li>
<li>Silexion Therapeutics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) shares fell 32.4% to $2.12 in pre-market trading. Silexion Therapeutics announced exercise of warrants for $3.3 million gross proceeds.</li>
<li>Avalon Holdings Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AWX#NYSE">AWX</a>) fell 19.2% to $2.90 in today's pre-market trading.</li>
<li>Coincheck Group N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNCK#NASDAQ">CNCK</a>) shares dipped 17.1% to $7.00 in pre-market trading after falling 4% on Wednesday.</li>
<li>Varex Imaging Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VREX#NASDAQ">VREX</a>) shares tumbled 12.2% to $11.94 in pre-market trading. Varex Imaging will report unaudited financial results for the first quarter of fiscal year 2025 following the close of regular trading on Thursday, Feb. 6.</li>
<li>Whirlpool Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHR#NYSE">WHR</a>) fell 10.6% to $116.00 in pre-market trading after the company reported worse-than-expected fourth-quarter revenue results and issued FY25 guidance below estimates.</li>
<li>ServiceNow, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) fell 9.4% to $1,035.79 in pre-market trading after the company reported worse-than-expected quarterly revenue results.</li>
<li>Orthofix Medical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) declined 9.1% to $17.01 in pre-market trading. Orthofix Medical will release its fourth quarter and full-year 2024 financial results on Tuesday, Feb. 25, before the opening bell.</li>
<li>First Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBNC#NASDAQ">FBNC</a>) fell 6.8% to $41.00 in pre-market trading following fourth-quarter earnings.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43300989/jim-cramer-this-industrial-stock-is-absolutely-terrific-first-solar-is-very-inexpensive">Jim Cramer: This Industrial Stock Is &#8216;Absolutely Terrific&#8217;, First Solar Is &#8216;Very Inexpensive&#8217;</a></li>
</ul>

Why Meta Platforms Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

Canaccord Genuity initiated coverage on Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>), a medical device company focused on the development, manufacture and commercialization of technology for the surgical treatment of spinal and broader orthopedic disorders.
Canaccord Genuity analyst Caitlin Cronin writes that over two years have passed since Orthofix merged with SeaSpine. With a new management team in place since early 2024, the company has successfully integrated the two teams and portfolios.
It is now ready to move forward with its long-term plan and unified strategy. The analyst is optimistic about Orthofix Medical&#8217;s unique offerings and plans for ongoing innovation, using its entire portfolio to drive growth across its various segments.
This cohesion is helping Orthofix Medical not only aim for above-market growth but also focus on cash generation and improve profit margins.
Canaccord Genuity has initiated with a Buy rating and a <a target="_blank" href="https://www.benzinga.com/quote/OFIX/analyst-ratings" rel="noreferrer noopener">price forecast of $24</a>.
The analyst Cronin adds that both 7D and ortho sub-segments are in Orthofix Medical&#8217;s highest growing markets, with the company estimating market growth of 10-12% in enabling tech and 5-6% in its ortho segment.
Overall, the company is targeting profitable growth. Additionally, Orthofix Medical&#8217;s current valuation appears attractive, trading well below the average of its small-cap and spine industry peers.
Third quarter 2024 net sales increased 7% year-over-year to $196.6 million, with 18% growth in U.S. Spine Fixation net sales driven by distribution expansion and further penetration in existing accounts, 9% growth in Bone Growth Therapies net sales and <a href="https://www.benzinga.com/pressreleases/24/11/b41802749/orthofix-reports-third-quarter-2024-results-reiterates-full-year-2024-financial-guidance-and-intro" target="_blank" rel="noreferrer noopener">13% growth in BGT Fracture net sales</a>.
The company expects 2024 sales of $795 million-$800 million compared to the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $796.6 million</a>.
The company sees adjusted EBITDA guidance of $64 million to $69 million and expects positive free cash flow for the second half of 2024.
Price Action: OFIX stock is down 0.05% at $18.35 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/01/43136830/lockheed-martin-secures-270-million-us-air-force-deal" target="_blank" rel="noreferrer noopener">Lockheed Martin Secures $270 Million US Air Force Deal For Next-Gen F-22 Infrared Defense</a></li>
</ul>
Image: Shutterstock

This Analyst Says Orthopedic-Focused Orthofix Medical Is Positioned For Growth

Comments

Orthofix Medical

Orthofix Medical (OFIX) Opciones

Orthofix Medical (NASDAQ:OFIX) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL